

Author index*

A

Abernethy DR (*see* Spyker et al). 2000;67:196-200 (Commentary)
Ademowo OG, Sodeinde O, Walker O. The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritis: evidence for decreased chloroquine metabolism in volunteers with pruritis. 2000;67:237-41
Affrime MB (*see* Gorski et al). 2000;67:32-43
Akimoto M (*see* Furuya et al). 2000;67:489-97
Allaire J (*see* Hamelin et al). 2000;67:466-77
Allegra A (*see* Buemi et al). 2000;67:427-31
Aloisi C (*see* Buemi et al). 2000;67:427-31
Andersen MP (*see* Marbury et al). 2000;67:7-15
Anderson GD (*see* Roby et al). 2000;67:451-7
Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. 2000;67:44-7
Arnold JMO (*see* Dzeka et al). 2000;67:299-304
Arnold JMO (*see* Feng et al). 2000;67:292-8
Atkinson AJ (*see* Spyker et al). 2000;67:196-200 (Commentary)
Avram MJ (*see* Niemann et al). 2000;67:342-50
Azie NE (*see* Fleishaker et al). 2000;67:498-503

B

Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ. Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation. 2000;67:382-90
Backman JT (*see* Varis et al). 2000;67:215-21
Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. 2000;67:689 (Letter)
Banken L (*see* Jorga et al). 2000;67:610-20
Bannon P (*see* Villeneuve et al). 2000;67:242-8
Banyai M, Thalhammer F, El Menyawi I, Heinz G, Traunmüller F, Siostrzonek P. Pharmacokinetics of cefpime during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000;67:368-72
Bastien G (*see* Isetta et al). 2000;67:323-5
Baudouy M (*see* Isetta et al). 2000;67:323-5
Beaune P (*see* Simon et al). 2000;67:432-7
Becker P (*see* Gorski et al). 2000;67:32-43
Becquemont L (*see* Simon et al). 2000;67:432-7
Beijnen JH (*see* Huiterna et al). 2000;67:621-30
Belle DJ (*see* Backman et al). 2000;67:382-90
Belpaire FM (*see* Hemeryck et al). 2000;67:283-92
Benowitz NL, Jacob P. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. 2000;67:653-9
Benowitz NL (*see* Chalon et al). 2000;67:391-7
Benowitz NL (*see* Dempsey et al). 2000;67:458-65
Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. 2000;67:413-8
Bernabei R (*see* Zuccalà et al). 2000;67:314-22
Besner JG (*see* du Souich et al). 2000;67:249-57
Blaak EE (*see* Schiffers et al). 2000;67:558-66
Blachke TF (*see* Chalon et al). 2000;67:391-7

*January, pp. 1-88; February, pp. 89-192; March, pp. 193-330; April, pp. 331-446; May, pp. 447-590; June, pp. 591-710. Index to the ASCPT meeting abstracts is located in the February issue.

Bokstein F (*see* Zylber-Katz et al). 2000;67:631-41
Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. 2000;67:351-9
Bouayad A (*see* Hamelin et al). 2000;67:466-77
Bouillon T (*see* Pollak et al). 2000;67:642-52
Braeckman RA (*see* Kemme et al). 2000;67:504-11
Brater DC, Daly WJ. Clinical pharmacology in the Middle Ages: principles that presage the 21st century. 2000;67:447-50 (Commentary)
Brater DC (*see* Mousa et al). 2000;67:267-74
Breddin HK (*see* Klinkhardt et al). 2000;67:305-13
Brodde OE (*see* Jakubetz et al). 2000;67:549-57
Brown NJ (*see* Xie et al). 2000;67:670-5
Brunner M (*see* Hollenstein et al). 2000;67:229-36
Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe MS, Pettinato G, Corsonello A, Senatore M, Frisina N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. 2000;67:427-31
Burggraaf J (*see* Kemme et al). 2000;67:504-11
Burri C (*see* Keiser et al). 2000;67:478-88
Burstein AH (*see* Roby et al). 2000;67:451-7

C

Caillé G (*see* du Souich et al). 2000;67:249-57
Callow ID (*see* Feng et al). 2000;67:292-8
Cantilena LR (*see* Spyker et al). 2000;67:196-200 (Commentary)
Carbonin P (*see* Zuccalà et al). 2000;67:314-22
Carel BJ (*see* Fleishaker et al). 2000;67:498-503
Carosella L (*see* Zuccalà et al). 2000;67:314-22
Cha JJ (*see* Yoon et al). 2000;67:567-76
Cha YN (*see* Chung et al). 2000;67:258-66
Cha YN (*see* Yoon et al). 2000;67:567-76
Chalon S, Moreno H, Benowitz NL, Hoffman BB, Blachke TF. Nicotine impairs endothelium-dependent dilatation in human veins *in vivo*. 2000;67:391-7
Chien JY (*see* Thummel et al). 2000;67:591-9
Childs A (*see* Kemme et al). 2000;67:504-11
Cho MH (*see* Chung et al). 2000;67:258-66
Chung WG, Kang JH, Park CS, Cho MH, Cha YN. Effect of age and smoking on *in vivo* CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. 2000;67:258-66
Clozel JP (*see* du Souich et al). 2000;67:249-57
Cocchi A (*see* Zuccalà et al). 2000;67:314-22
Cohen AF (*see* Kemme et al). 2000;67:504-11
Corica F (*see* Buemi et al). 2000;67:427-31
Corsonello A (*see* Buemi et al). 2000;67:427-31
Crespi CL (*see* Sata et al). 2000;67:48-56
Cutler DL (*see* Gorski et al). 2000;67:32-43

D

Daily JP (*see* Greenblatt et al). 2000;67:335-41
Daly WJ (*see* Brater and Daly). 2000;67:447-50 (Commentary)
Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. 2000;67:530-7

De Carolis MP (see Romagnoli et al). 2000;67:676-82
 de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. 2000;67:360-7
 De Maeght S (see Villeneuve et al). 2000;67:242-8
 De Vriendt C (see Hemeryck et al). 2000;67:283-92
 de Waziers I (see Simon et al). 2000;67:432-7
 DeBrot DJ (see Goldstein et al). 2000;67:419-26
 Delacher S (see Hollenstein et al). 2000;67:229-36
 Delogu AB (see Romagnoli et al). 2000;67:676-82
 Dempsey D, Jacob P, Benowitz NL. Nicotine metabolism and elimination kinetics in newborns. 2000;67:458-65
 Desagnés P (see Hamelin et al). 2000;67:466-77
 Deutsch PJ (see Boruchoff et al). 2000;67:351-9
 Diener HC. Eletriptan and coronary artery. 2000;67:326 (Letter)
 Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. 2000;67:512-20
 Dishy V (see Xie et al). 2000;67:670-5
 Dobrev D (see Grossmann et al). 2000;67:22-31
 Dresser GK (see Bailey and Dresser). 2000;67:689 (Letter)
 Dryer DA (see Roby et al). 2000;67:451-7
 du Souich P, Besner JG, Clozel JP, Welker HA, Lefebvre M, Caillé G. Nonlinear kinetics and pharmacologic response to mibepradil. 2000;67:249-57
 Dumesnil J (see Hamelin et al). 2000;67:466-77
 Durol ALB (see Greenblatt et al). 2000;67:335-41
 Dzeka TN, Kuzminski P, Arnold JMO. Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin. 2000;67:299-304

E

Ebert U, Oertel R, Kirch W. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. 2000;67:538-48
 Edsbaäcker S (see Seidegård et al). 2000;67:373-81
 Eichler HG (see Hollenstein et al). 2000;67:229-36
 El Menawy I (see Banyai et al). 2000;67:368-72
 Elizondo G (see Sata et al). 2000;67:48-56
 Elliott C, Newman N, Madan A. Gentamicin effects on urinary electrolyte excretion in healthy subjects. 2000;67:16-21
 Enders-Klein C (see Niemann et al). 2000;67:342-50
 Engel J (see Erb et al). 2000;67:660-9
 Erb K, Pechstein B, Schueler A, Engel J, Hermann R. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study. 2000;67:660-9
 Ericsson Ö (see Keiser et al). 2000;67:478-88
 Erovic B (see Hollenstein et al). 2000;67:229-36

F

Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. 2000;67:438-41
 Feng Q, Lambert ML, Callow ID, Arnold JMO. Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure. 2000;67:292-8
 Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. 2000;67:498-503
 Flockhart DA (see Benton et al). 2000;67:413-8
 Flockhart DA (see Yoon et al). 2000;67:567-76
 Foss JF, O'Connor M, Garrison T, Osinski J, Roizen MF, Moss J (see Yuan et al). 2000;67:398-404
 Foss JF (see Yuan et al). 2000;67:398-404
 Fotteler B (see Jorga et al). 2000;67:610-20

Frisina N (see Buemi et al). 2000;67:427-31
 Fujimura A (see Harada et al). 2000;67:405-12
 Funck-Brentano C (see Simon et al). 2000;67:432-7
 Furue H (see Takanaga et al). 2000;67:201-14
 Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T. Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. 2000;67:683-8

Furuya A, Kato N, Jingu S, Akimoto M, Higuchi S, Suwa T, Ogata H. Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects. 2000;67:489-97

G

Gainer JV (see Xie et al). 2000;67:670-5
 Garaffo R (see Isetta et al). 2000;67:323-5
 Giacobbe MS (see Buemi et al). 2000;67:427-31
 Gitter BD (see Goldstein et al). 2000;67:419-26
 Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrot DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. 2000;67:419-26
 Gomori JM (see Zylber-Katz et al). 2000;67:631-41
 Gonzalez FJ (see Sata et al). 2000;67:48-56
 Goree RE (see Xie et al). 2000;67:670-5
 Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. 2000;67:32-43
 Graf JA (see Greenblatt et al). 2000;67:335-41
 Graff J (see Klinkhardt et al). 2000;67:305-13
 Grasing KW (see Boruchoff et al). 2000;67:351-9
 Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Alprazolam-ritonavir interaction: implications for product labeling. 2000;67:335-41
 Grossmann M, Dobrev D, Himmel HM, Kirch W. Local venous response to N-desethylamiodarone in humans. 2000;67:22-31
 Grözinger M (see Härtter et al). 2000;67:1-6
 Gruppo Italiano di Farmacopepidemiologia nell'Anziano (GIFA) investigators (see Zuccalà et al). 2000;67:314-22

H

Haefeli WE (see Arnet and Haefeli). 2000;67:44-7
 Haehner-Daniels B (see Gorski et al). 2000;67:32-43
 Haines JL (see Xie et al). 2000;67:670-5
 Hall SD (see Gorski et al). 2000;67:32-43
 Hall SD (see Mousa et al). 2000;67:267-74
 Hamelin BA, Bouayad A, Méthot J, Jobin J, Desagnés P, Poirier P, Allaïre J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. 2000;67:466-77
 Hanai H (see Furuta et al). 2000;67:683-8
 Harada K, Kawaguchi A, Ohmori M, Fujimura A. Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors. 2000;67:405-12
 Harder S (see Klinkhardt et al). 2000;67:305-13
 Harmatz JS (see Greenblatt et al). 2000;67:335-41
 Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. 2000;67:1-6
 Harvey AM (see Spyker et al). 2000;67:196-200 (Commentary)
 Harvey BE (see Spyker et al). 2000;67:196-200 (Commentary)
 Harvey ED (see Spyker et al). 2000;67:196-200 (Commentary)
 Hashiguchi M (see Shiga et al). 2000;67:222-8

Hatorp V (see Marbury et al). 2000;67:7-15
Heinz G (see Banyai et al). 2000;67:368-72
Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. 2000;67:283-92
Henthorn TK (see Niemann et al). 2000;67:342-50
Hermann R (see Erb et al). 2000;67:660-9
Hiemke C (see Härtter et al). 2000;67:1-6
Higuchi S (see Furuya et al). 2000;67:489-97
Higuchi S (see Takanaga et al). 2000;67:201-14
Himmel HM (see Grossmann et al). 2000;67:22-31
Hochstein HD (see McMahon et al). 2000;67:70 (Letter)
Hoffman BB (see Chalon et al). 2000;67:391-7
Hoffman JL (see Greenblatt et al). 2000;67:335-41
Hofmann U (see Dilger et al). 2000;67:512-20
Hollenstein U, Brunner M, Mayer BX, Delacher S, Erovic B, Eichler HG, Müller M. Target site concentrations after continuous infusion and bolus injection of cefipime to healthy volunteers. 2000;67:229-36
Huang WC (see Marbury et al). 2000;67:7-15
Huitema ADR, Mathôt RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. 2000;67:621-30

I

Irie S (see Takanaga et al). 2000;67:201-14
Isetta C, Garaffo R, Bastian G, Jourdan J, Baudouy M, Milano G. Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine. 2000;67:323-5
Ishizaki T (see Furuta et al). 2000;67:683-8
Iyengar S (see Goldstein et al). 2000;67:419-26

J

Jacob P (see Benowitz and Jacob). 2000;67:653-9
Jacob P (see Dempsey et al). 2000;67:458-65
Jaillon P (see Simon et al). 2000;67:432-7
Jakubetz J, Schmuck S, Wochatz G, Ruhland B, Poller U, Radke J, Brodde OE. Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzapine. 2000;67:549-57
Jang IJ (see Yoon et al). 2000;67:567-76
Jilma B. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Reply)
Jingu S (see Furuya et al). 2000;67:489-97
Jobin J (see Hamelin et al). 2000;67:466-77
Jorga K, Banken L, Fotteler B, Snell P, Steiner JL. Population pharmacokinetics of levodopa in parkinsonian patients treated with lecaponine. 2000;67:610-20
Jourdan J (see Isetta et al). 2000;67:323-5

K

Kalhorn TF (see Manyike et al). 2000;67:275-82
Kang JH (see Chung et al). 2000;67:258-66
Kantor E (see Roby et al). 2000;67:451-7
Karim A (see Kemme et al). 2000;67:504-11
Karrison T (see Yuan et al). 2000;67:398-404
Kasanuki H (see Shiga et al). 2000;67:222-8
Kato N (see Furuya et al). 2000;67:489-97
Kawaguchi A (see Harada et al). 2000;67:405-12
Kawano K (see Takanaga et al). 2000;67:201-14
Keiser J, Ericsson Ö, Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. 2000;67:478-88

Kelly A (see Feely et al). 2000;67:438-41
Kemme MJB, Burgraaf J, Schoemaker RC, Paulson S, Karim A, Lentjes EGWM, Childs A, Braeckman RA, Cohen AF. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. 2000;67:504-11
Kharasch ED (see Manyike et al). 2000;67:275-82
Kim KA (see Yoon et al). 2000;67:567-76
Kim RB (see Kinironi et al). 2000;67:577 (Reply)
Kim RB (see Xie et al). 2000;67:670-5
Kimura M (see Takanaga et al). 2000;67:201-14
Kinironi MT, O'shea D, Kim RB, Wood AJJ, Wilkinson GR. Erythromycin breath test. 2000;67:577 (Reply)
Kirch W (see Ebert et al). 2000;67:538-48
Kirch W (see Grossmann et al). 2000;67:22-31
Kirchmaier CM (see Klinkhardt et al). 2000;67:305-13
Kivistö KT (see Backman et al). 2000;67:382-90
Kivistö KT (see Varis et al). 2000;67:215-21
Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harde S. Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR12156A. 2000;67:305-13
Klotz U (see Dilger et al). 2000;67:512-20
Kramer Nielsen K (see Marbury et al). 2000;67:7-15
Krejcie TC (see Niemann et al). 2000;67:342-50
Kuroiwa Y (see Nakajima et al). 2000;67:57-69
Kusma SE (see Boruchoff et al). 2000;67:351-9
Kuzminski P (see Dzeka et al). 2000;67:299-304

L

Lambert ML (see Feng et al). 2000;67:292-8
L'Ecuyer L, De Maeght S, Bannon P (see Villeneuve et al). 2000;67:242-8
L'Ecuyer L (see Villeneuve et al). 2000;67:242-8
Lefebvre M (see du Souich et al). 2000;67:249-57
Lefebvre RA (see Hemeryck et al). 2000;67:283-92
Lentjes EGWM (see Kemme et al). 2000;67:504-11
Lossos Z (see Zylber-Katz et al). 2000;67:631-41
Love MP (see Davie et al). 2000;67:530-7
Lown KE (see Thummel et al). 2000;67:591-9
Luciano R (see Romagnoli et al). 2000;67:676-82

M

Madan A (see Elliot et al). 2000;67:16-21
Mäenpää J (see Backman et al). 2000;67:382-90
Mahnel R (see Klinkhardt et al). 2000;67:305-13
Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. 2000;67:275-82
Marbury TC, Rucke JL, Hatorp V, Andersen MP, Kramer Nielsen K, Huang WC, Strange P. Pharmacokinetics of repaglinide in subjects with renal impairment. 2000;67:7-15
Mary-Krause M (see Simon et al). 2000;67:432-7
Mathôt RAA (see Huitema et al). 2000;67:621-30
Matsukuma K (see Takanaga et al). 2000;67:201-14
Matsuo H (see Takanaga et al). 2000;67:201-14
Mayer BX (see Hollenstein et al). 2000;67:229-36
McCrea J (see Boruchoff et al). 2000;67:351-9
McGettigan P (see Feely et al). 2000;67:438-41
McMahon EG, Vargas R, Hochstein HD. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Letter)
McMurray JJV (see Davie et al). 2000;67:530-7
Merle Y (see Trély et al). 2000;67:600-9
Mertzanis P (see Greenblatt et al). 2000;67:335-41
Méthot J (see Hamelin et al). 2000;67:466-77

Milano G (see Isetta et al). 2000;67:323-5
 Miller VP (see Sata et al). 2000;67:48-56
 Moreno H (see Chalon et al). 2000;67:391-7
 Moss J (see Yuan et al). 2000;67:398-404
 Mousa O, Brater DC, Sundblad KJ, Hall SD. The interaction of diltiazem with simvastatin. 2000;67:267-74
 Mouton JW (see de Hoog et al). 2000;67:360-7
 Müller M (see Hollenstein et al). 2000;67:229-36
 Murakami H (see Takanaga et al). 2000;67:201-14

N

Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the *CYP2A6* gene in humans. 2000;67:57-69
 Nelson SD (see Thummel et al). 2000;67:591-9
 Neuvonen PJ (see Backman et al). 2000;67:382-90
 Neuvonen PJ (see Varis et al). 2000;67:215-21
 Newmar N (see Elliott et al). 2000;67:16-21
 Niemann Cü, Henthorn TK, Krejcic TC, Shanks CA, Enders-Klein C, Avram MJ. Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. 2000;67:342-50

O

O'Connor M (see Yuan et al). 2000;67:398-404
 Oertel R (see Ebert et al). 2000;67:538-48
 Ogata H (see Furuya et al). 2000;67:489-97
 Ohashi K (see Furuta et al). 2000;67:683-8
 Ohmori M (see Harada et al). 2000;67:405-12
 Ohnishi A (see Takanaga et al). 2000;67:201-14
 Orii Y (see Takanaga et al). 2000;67:201-14
 O'shea D (see Kinirons et al). 2000;67:577 (Reply)
 Osinski J (see Yuan et al). 2000;67:398-404

P

Pahor M (see Zuccalà et al). 2000;67:314-22
 Papacci P (see Romagnoli et al). 2000;67:676-82
 Park CS (see Chung et al). 2000;67:258-66
 Park CW (see Yoon et al). 2000;67:567-76
 Paulson S (see Kemme et al). 2000;67:504-11
 Pechstein B (see Erb et al). 2000;67:660-9
 Peck CC (see Spyker et al). 2000;67:196-200 (Commentary)
 Pedone C (see Zuccalà et al). 2000;67:314-22
 Pettinato G (see Buemi et al). 2000;67:427-31
 Piersigilli F (see Romagnoli et al). 2000;67:676-82
 Poirier P (see Hamelin et al). 2000;67:466-77
 Polimeni V (see Romagnoli et al). 2000;67:676-82
 Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. 2000;67:642-52
 Poller U (see Jakubetz et al). 2000;67:549-57
 Pons G (see Tréluyer et al). 2000;67:600-9

R

Radke J (see Jakubetz et al). 2000;67:549-57
 Raunio H (see Sata et al). 2000;67:48-56
 Reidenberg MM. Are we treating health or physical appearance when we prescribe drugs for obesity? 2000;67:193-5 (Commentary)
 Rikihisa T (see Shiga et al). 2000;67:222-8
 Ro H (see Thummel et al). 2000;67:591-9
 Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's Wort: effect on CYP3A4 activity. 2000;67:451-7

Rodenhuis S (see Huitema et al). 2000;67:621-30
 Roizen MF (see Yuan et al). 2000;67:398-404
 Romagnoli C, De Carolis MP, Papacci P, Polimeni V, Luciano R, Piersigilli F, Delogu AB, Tortorolo G. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. 2000;67:676-82
 Röschke J (see Härtter et al). 2000;67:1-6
 Ruckle JL (see Marbury et al). 2000;67:7-15
 Ruhland B (see Jakubetz et al). 2000;67:549-57
 Rumack BH (see Spyker et al). 2000;67:196-200 (Commentary)

S

Sale M (see Benton et al). 2000;67:413-8
 Sapone A (see Sata et al). 2000;67:48-56
 Saris WHM (see Schiffelers et al). 2000;67:558-66
 Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity. 2000;67:48-56
 Sawada Y (see Takanaga et al). 2000;67:201-14
 Schellens JHM (see Huitema et al). 2000;67:621-30
 Schiffelers SLH, Blaak EE, Saris WHM, van Baak MA. In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use. 2000;67:558-66
 Schmuck S (see Jakubetz et al). 2000;67:549-57
 Schoemaker RC (see de Hoog et al). 2000;67:360-7
 Schoemaker RC (see Kemme et al). 2000;67:504-11
 Schueler A (see Erb et al). 2000;67:660-9
 Schuster BG (see Wesche et al). 2000;67:521-9
 Schwartz A (see Zyber-Katz et al). 2000;67:631-41
 Seibold JR (see Boruchoff et al). 2000;67:351-9
 Seidegård J, Simonsson M, Edsbaäcker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. 2000;67:373-81
 Semlali A (see Tréluyer et al). 2000;67:600-9
 Senatore M (see Buemi et al). 2000;67:427-31
 Shader RI (see Greenblatt et al). 2000;67:335-41
 Shafer SL (see Pollak et al). 2000;67:642-52
 Shanks CA (see Niemann et al). 2000;67:342-50
 Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. 2000;67:222-8
 Shin SG (see Yoon et al). 2000;67:567-76
 Shirai N (see Furuta et al). 2000;67:683-8
 Shon JH (see Yoon et al). 2000;67:567-76
 Siegal T (see Zyber-Katz et al). 2000;67:631-41
 Simon T, Bequemont L, Mary-Krause M, de Waziers I, Beaune P, Funk-Brentano C, Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. 2000;67:432-7
 Simonsson M (see Seidegård et al). 2000;67:373-81
 Siostrzonek P (see Banyai et al). 2000;67:368-72
 Sisson TA (see Fleishaker et al). 2000;67:498-503
 Slattery JT (see Manyike et al). 2000;67:275-82
 Slattery JT (see Thummel et al). 2000;67:591-9
 Snell P (see Jorga et al). 2000;67:610-20
 Sodeinde O (see Ademowo et al). 2000;67:237-41
 Sofowora G (see Xie et al). 2000;67:670-5
 Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ, Woosley RL, Abernethy DR, Cantilena LR. Assessment and reporting of clinical pharmacology information in drug labeling. 2000;67:196-200 (Commentary)
 Steimer JL (see Jorga et al). 2000;67:610-20
 Stein CM (see Xie et al). 2000;67:670-5
 Stocker P (see Sata et al). 2000;67:48-56
 Strange P (see Marbury et al). 2000;67:7-15
 Sturgill MG (see Boruchoff et al). 2000;67:351-9

Sundblad KJ (see Mousa et al). 2000;67:267-74
Suwa T (see Furuya et al). 2000;67:489-97

T

Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furue H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. 2000;67:201-14
Takahashi M (see Furuta et al). 2000;67:683-8
Tanaka T (see Takanaga et al). 2000;67:201-14
Thalhammer F (see Banyai et al). 2000;67:368-72
Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. 2000;67:591-9
Tibben MM (see Huitema et al). 2000;67:621-30
Todd LE (see Goldstein et al). 2000;67:419-26
Tortorolo G (see Romagnoli et al). 2000;67:676-82
Traunmüller F (see Banyai et al). 2000;67:368-72
Tréliuyer JM, Merlé Y, Semlali A, Pons G. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. 2000;67:600-9
Turgeon J (see Hamelin et al). 2000;67:466-77

U

Urae A (see Shiga et al). 2000;67:222-8
Urae A (see Takanaga et al). 2000;67:201-14
Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. 2000;67:331-4 (Commentary)

V

van Baak MA (see Schiffers et al). 2000;67:558-66
van den Anker JN (see de Hoog et al). 2000;67:360-7
Vargas R (see McMahon et al). 2000;67:70 (Letter)
Varis T, Backman JT, Kivistö KT, Neuvonen PJ. Diltiazem and mibepradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. 2000;67:215-21
Villeneuve JP, L'Ecuyer L, De Maeght S, Bannon P. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. 2000;67:242-8
von Moltke LL (see Greenblatt et al). 2000;67:335-41

W

Walker O (see Ademowo et al). 2000;67:237-41
Wang O (see Goldstein et al). 2000;67:419-26

Wang WX (see Wesche et al). 2000;67:521-9
Watkins PB. Erythromycin breath test. 2000;67:577 (Letter)
Watkins PB (see Thummel et al). 2000;67:591-9
Weigmann H (see Härtter et al). 2000;67:1-6
Welker HA (see du Souich et al). 2000;67:249-57
Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. 2000;67:521-9
Westrup D (see Klinkhardt et al). 2000;67:305-13
Wilkinson GR (see Kinirons et al). 2000;67:577 (Reply)
Winchell GA (see Boruchoff et al). 2000;67:351-9
Wochatz G (see Jakubetz et al). 2000;67:549-57
Wood AJJ (see Kinirons et al). 2000;67:577 (Reply)
Wood AJJ (see Xie et al). 2000;67:670-5
Woosley RL (see Benton et al). 2000;67:413-8
Woosley RL (see Spyker et al). 2000;67:196-200 (Commentary)
Woosley RL (see Wesche et al). 2000;67:521-9
Wrighton SA (see Backman et al). 2000;67:382-90

X

Xiao F (see Furuta et al). 2000;67:683-8
Xie HK, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, Brown NJ, Goree RE, Haines JL, Wood AJJ. Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. 2000;67:670-5

Y

Yamagishi S (see Nakajima et al). 2000;67:57-69
Yamamoto H (see Nakajima et al). 2000;67:57-69
Yamamoto T (see Nakajima et al). 2000;67:57-69
Yokoi T (see Nakajima et al). 2000;67:57-69
Yoon YR, Cha JJ, Shon JH, Kim KA, Cha YN, Jang JJ, Park CW, Shin SG, Flockhart DA. Relationship of paroxetine disposition to metoprolol metabolic ratio and *CYP2D6*10* genotype of Korean subjects. 2000;67:567-76
Yuan CS, Foss JF, O'Connor M, Garrison T, Osinski J, Roizen MF, Moss J. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. 2000;67:398-404

Z

Zheng W (see Sata et al). 2000;67:48-56
Zuccalà G, Pedone C, Coccochi A, Pahor M, Carosella L, Carbonin P, Bernabei R, Gruppo Italiano di Farmacopeidemiologia nell'Anziano (GIFA) investigators. Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study. 2000;67:314-22
Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. 2000;67:631-41

Subject index*

A

Abciximab

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Acetaminophen

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82
Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9

Adrogolide hydrochloride

Adrogolide hydrochloride (USAN List No. 423). 2000;67:74

Age factors

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Aged

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20
Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccala et al). 2000;67:314-22

Alemcinal

Alemcinal (USAN List No. 423). 2000;67:74

Almotriptan

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503

Alprazolam

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

American Society for Clinical Pharmacology and Therapeutics

Abstract of annual meeting. 2000;67:89-192
Annual meeting program. 2000;67:79-87
New website announcement. 2000;67:328
New members of the Society. 2000;67:582
2000 Annual meeting abstract books announcement. 2000;67:584
2000 Annual meeting audiocassettes announcement. 2000;67:585
2000-2001 Officers, committee chairpersons, and board members. 2000;67:690
Call for scientific program abstracts. 2000;67:691

Amiloxate

Amiloxate (USAN List No. 423). 2000;67:75

Amiodarone

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31
Population pharmacokinetics of long-term oral amiodarone therapy (Pollak et al). 2000;67:642-52

Amoxicillin

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

*January, pp. 1-88; February, pp. 89-192; March, pp. 193-330; April, pp. 331-446; May, pp. 447-590; June, pp. 591-710. Index to the ASCPT meeting abstracts is located in the February issue.

Analgesics, non-narcotic

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70

Antibiotics, aminoglycoside

Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21

Antihistamines

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Aspirin

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin (Dzeka et al). 2000;67:299-304

Authorship

The forgotten author. 2000;67:326 (Letter)

B

Bayes theorem

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods (Huitema et al). 2000;67:621-30

Blood flow velocity

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor (Kemme et al). 2000;67:504-11

Blood volume

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

Body image

Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Brain

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Brain neoplasms

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Budesonide

Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol (Seidegård et al). 2000;67:373-81

C

Caffeine

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Calcium channel blockers

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccalà et al). 2000;67:314-22

Carbamates

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Carbon monoxide

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Carboplatin

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods (Huitema et al). 2000;67:621-30

Cardiovascular system

Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5

Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9

Cefpirome

Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000;67:368-72

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers (Hollenstein et al). 2000;67:229-36

Cerebrospinal fluid

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Chloroquine

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Chronotherapy

Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Cimetidine

Effect of cimetidine and probenecid on pilsicainide renal clearance in humans (Shiga et al). 2000;67:222-8

Clarithromycin

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin (Boruchoff et al). 2000;67:351-9

Clopidogrel

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Commentaries

Commentaries. 2000;67:193-200, 447-50

Contraceptives, oral

Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol (Seidegård et al). 2000;67:373-81

Coronary arteries

Eltiptan and coronary artery (Diener). 2000;67:326 (Letter)

Corrections

Correction to Lewis et al. "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction." Vol 62, 1997, pages 464-75. 2000;67:431

Correction to Tan et al. "Vanadate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects." Vol 6, 1999, pages 275-81. 2000;67:367

Cotinine

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Crofelemer

Crofelemer (USAN List No. 423). 2000;67:76

Cyclosporine

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Cytochrome P-450

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82

CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56

Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (Nakajima et al). 2000;67:57-69

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

St. John's Wort: effect on CYP3A4 activity (Roby et al). 2000;67:451-7

In vivo effects of interleukin-10 on human cytochrome P450 activity (Gorski et al). 2000;67:32-43

Cytochrome P-450 CYP1A2

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Cytochrome P-450 CYP2C19

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Cytochrome P-450 CYP2D6

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Cytochrome P-450 CYP2E1

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82

D

Desethylchloroquine

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Diltiazem

Diltiazem and mibepradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone (Varis et al). 2000;67:215-21

The interaction of diltiazem with simvastatin (Mousa et al). 2000; 67:267-74

Diphenhydramine

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Docosanol

Docosanol (USAN List No. 424). 2000;67:330

Drug administration

Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000; 67:368-72

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers (Hollenstein et al). 2000;67:229-36

Drug antagonism

Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12

Drug delivery systems

Erratic patient compliance with prescribed drug regimens: target for drug delivery systems (Urquhart). 2000;67:331-4 (Commentary)

Drug information

Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)

Drug interactions

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

The interaction of diltiazem with simvastatin (Mousa et al). 2000;67:267-74

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Drug labeling

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)

Drug toxicity

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9

Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5

Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9

Duodenal ulcer

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

E

Electroencephalography

Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48

Electrolytes

Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21

Eletriptan

Eletriptan and coronary artery (Diener). 2000;67:326 (Letter)

Eletriptan hydrobromide (USAN List No. 423). 2000;67:73

Entecavir

Entecavir (USAN List No. 424). 2000;67:329

Enzacamene

Enzacamene (USAN List No. 423). 2000;67:272

Erythromycin

Erythromycin breath test (Watkins) (Letter): (Kinirons et al) (Reply) 2000;67:577

Ethanol

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9

Evernimicin

Evernimicin (USAN List No. 426). 2000;67:588

Exatecan mesylate

Exatecan mesylate (USAN List No. 424). 2000;67:329

Exons

CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56

Ezlopitant

Ezlopitant (USAN List No. 424). 2000;67:330

F

Fiduxosin hydrochloride

Fiduxosin hydrochloride (USAN List No. 424). 2000;67:330

Fluorocytosine

Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5

Fluorouracil

Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorouracil (Isetta et al). 2000;67:323-5

Fluvastatin

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Fluvoxamine

Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6

Food-drug interactions

Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)

Fulvestrant

Fulvestrant (USAN List No. 423). 2000;67:75

G

Gemifloxacin mesylate

Gemifloxacin mesylate (USAN List No. 423). 2000;67:72

Gene deletion

Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (Nakajima et al). 2000;67:57-69

Gentamicins

Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21

Glomerulonephritis, IGA

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Glutathione transferases

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and taceine hepatotoxicity (Simon et al). 2000;67:432-7

Glycoproteins

Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects (Furuya et al). 2000;67:489-97

Gonads

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist terevelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Grapefruit juice

Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects (Takanaga et al). 2000;67:201-14

H

Halofantrine

Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9

Health

Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Heart failure

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure (Feng et al). 2000;67:292-8

Helicobacter pylori

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Hemoglobin

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccalà et al). 2000;67:314-22

History of Medicine, Medieval

Clinical pharmacology in the Middle Ages: principles that presage the 21st century (Brater and Daly). 2000;67:447-50 (Commentary)

Homosalate

Homosalate (USAN List No. 423). 2000;67:73

Hydroxylases

CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56

Hypertension

Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5

Hypoglycemic agents

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

I

Ibrutinomab tiuxetan

Ibrutinomab tiuxetan (USAN List No. 426). 2000;67:587

Ibuprofen

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Immunoglobulins, gamma-Chain

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Indinavir

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin (Boruchoff et al). 2000;67:351-9

Indocyanine

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

Infant, newborn

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Nicotine metabolism and elimination kinetics in newborns (Dempsey et al). 2000;67:458-65

Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method (Tréliuyer et al). 2000;67:600-9

Vancomycin population pharmacokinetics in neonates (de Hoog et al). 2000;67:360-7

Insulin

Insulin detemir (USAN List No. 426). 2000;67:589

Interleukin-10

In vivo effects of interleukin-10 on human cytochrome P450 activity (Gorski et al). 2000;67:32-43

Iron sucrose

Iron sucrose (USAN List No. 426). 2000;67:587

Izonsteride

Izonsteride (USAN List No. 425). 2000;67:445

K

Kidney diseases

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Kidneys

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Korea

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76

L

Lanepitant

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

Lasofoxifene tartrate

Lasofoxifene tartrate (USAN List No. 425). 2000;67:443

Leflunomide

Leflunomide (USAN List No. 426). 2000;67:590

Letters to the Editor

Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. 2000;67:689 (Letter)

Diener HC. Eletriptan and coronary artery. 2000;67:326 (Letter)

McMahon EG, Vargas R, Hochstein HD. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Letter)

Watkins PB. Erythromycin breath test. 2000;67:577 (Letter)

Levodopa

Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Liatermin

Liatermin (USAN List No. 426). 2000;67:589

Lipids

In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Liver

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor (Kemme et al). 2000;67:504-11

Liver transplantation

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Lovastatin

Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)

Lymphoma

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

M

Maxacalcitol

Maxacalcitol (USAN List No. 426). 2000;67:590

Melarsoprol

Investigations of the metabolites of the trypanocidal drug melarsoprol (Keiser et al). 2000;67:478-88

Melatonin

Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6

Mequinol

Mequinol (USAN List No. 425). 2000;67:443

Meradimate

Meradimate (USAN List No. 423). 2000;67:73

Methotrexate

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Methylnaltrexone

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time (Yuan et al). 2000;67:398-404

Metoprolol

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Hemeryck et al). 2000;67:283-292

Relationship of paroxetine disposition to metoprolol metabolic ratio and *CYP2D6*10* genotype of Korean subjects (Yoon et al). 2000;67:567-76

Significant interaction between the nonprescription antihistamine diphenhydramine and the *CYP2D6* substrate metoprolol in healthy men with high or low *CYP2D6* activity (Hamelin et al). 2000;67:466-77

Mibepradil

Diltiazem and mibepradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone (Varis et al). 2000;67:215-21

Nonlinear kinetics and pharmacologic response to mibepradil (du Souich et al). 2000;67:249-57

Midazolam

Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90

Phosystigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Motexafin gadolinium

Motexafin gadolinium (USAN List No. 425). 2000;67:445

Motexafin lutetium

Motexafin lutetium (USAN List No. 425). 2000;67:444

Moxonidine

Moxonidine (USAN List No. 425). 2000;67:445

N

Nadolol

In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Netilmicin

Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method (Trélyuer et al). 2000;67:600-9

Nicotine

Deficient cotinine formation from nicotine is attributed to the whole deletion of the *CYP2A6* gene in humans (Nakajima et al). 2000;67:57-69

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Nisoldipine

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects (Takanaga et al). 2000;67:201-14

Nonacog alfa

Nonacog alfa (USAN List No. 426). 2000;67:588

Norepinephrine

Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin (Dzeka et al). 2000;67:299-304

O

Obesity

Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Octinoxate

Octinoxate (USAN List No. 423). 2000;67:74

Octisalate

Octisalate (USAN List No. 423). 2000;67:75

Olanexidine hydrochloride

Olanexidine hydrochloride (USAN List No. 427). 2000;67:694

Omeprazole

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Opioids

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time (Yuan et al). 2000;67:398-404

Oseltamivir phosphate

Oseltamivir phosphate (USAN List No. 427). 2000;67:694

Osteoarthritis

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

P

Pain

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

Pantoprazole sodium

Pantoprazole sodium (USAN List No. 427). 2000;67:694

Parkinson disease

Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Paroxetine

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Hemeryck et al). 2000;67:283-292

Relationship of paroxetine disposition to metoprolol metabolic ratio and *CYP2D6*10* genotype of Korean subjects (Yoon et al). 2000;67:567-76

Patient compliance

Erratic patient compliance with prescribed drug regimens: target for drug delivery systems (Urquhart). 2000;67:331-4 (Commentary)

Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

Perflexane

Perflexane (USAN List No. 425). 2000;67:444

Perflutren

Perflutren (USAN List No. 425). 2000;67:444

Pharmacology, clinical

Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)

Clinical pharmacology in the Middle Ages: principles that presage the 21st century (Brater and Daly). 2000;67:447-50 (Commentary)

Physostigmine

Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48

Piboserod hydrochloride

Piboserod hydrochloride (USAN List No. 427). 2000;67:695

Piprozelesin hydrobromide

Piprozelesin hydrobromide (USAN List No. 427). 2000;67:695

Pilsicainide

Effect of cimetidine and probenecid on pilsicainide renal clearance in humans (Shiga et al). 2000;67:222-8

Piperidines

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Pirenzepine

Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Pituitary gland

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Polymorphism (genetic)

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7

Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5

Posaconazole

Posaconazole (USAN List No. 427). 2000;67:693

Prinomastat

Prinomastat (USAN List No. 427). 2000;67:693

Probenecid

Effect of cimetidine and probenecid on pilsicainide renal clearance in humans (Shiga et al). 2000;67:222-8

Propafenone

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20

Prophylaxis

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:678-82

Propranolol

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Proteinuria

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Pruritus

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Q

Quinidine

Greater quinidine-induced QTc interval prolongation in women (Benton et al). 2000;67:413-8

R

Receptors, adrenergic

Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12

Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Receptors, adrenergic, beta

Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5

In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Receptors, neuropeptide Y

Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure (Feng et al). 2000;67:292-8

Rifampin

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20

Ritonavir

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

Rivastigmine

Rivastigmine (USAN List No. 426). 2000;67:588

S**Self administration**

Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

Serotonin uptake inhibitors

Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6

Simvastatin

The interaction of diltiazem with simvastatin (Mousa et al). 2000; 67:267-74

Smoking

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67: 258-66

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Statins

Growth in use of statins after trials is not targeted to most appropriate patients (Feely et al). 2000;67:438-41

Systole

Greater quinidine-induced QTc interval prolongation in women (Benton et al). 2000;67:413-8

T**Tacrine**

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7

Tamsulosin

Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12

Tangeretin

Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90

Tangerine juice

Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90

Tagaserod

Tagaserod (USAN List No. 427). 2000;67:696

Tesmilifene hydrochloride

Tesmilifene hydrochloride (USAN List No. 427). 2000;67:695

Teverelix

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Time factors

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects (Takanaga et al). 2000;67:201-14

Tolcapone

Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Troxacitabine

Troxacitabine (USAN List No. 427). 2000;67:696

U**United States Adopted Names Council**

USAN Council. 2000;67:72-8, 329-30, 443-5, 587-90, 693-6

V**Vancomycin**

Vancomycin population pharmacokinetics in neonates (de Hoog et al). 2000;67:360-7

Vofopitant dihydrochloride

Vofopitant dihydrochloride (USAN List No. 427). 2000;67:696

Vasodilation

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31

Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Veins

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31

Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Verapamil

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503

Vitamins

Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

